RT @CochraneKidney: New Cochrane Review Update: Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppress…
RT @CochraneKidney: New Cochrane Review Update: Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppress…
Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients https://t.co/PBJt4oRTuG Systematic Review from @CochraneKidney includes 70 studies with 17,462 randomised participants.
RT @CochraneKidney: New Cochrane Review Update: Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppress…
RT @CochraneKidney: New Cochrane Review Update: Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppress…
RT @CochraneKidney: New Cochrane Review Update: Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppress…
RT @CochraneKidney: New Cochrane Review Update: Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppress…
RT @CochraneKidney: New Cochrane Review Update: Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppress…
New Cochrane Review Update: Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients. Discover the latest #CochraneEvidence here: https://t.co/VjCv8eOkfe #kidneytransplant #transplantati